Medication Transition from Flupentixol/Melitracen to Propranolol

Considerations for Propranolol Initiation

• The American College of Cardiology recommends checking for contraindications, including heart block, asthma, decompensated heart failure, and hypotension, before initiating propranolol 1
• The American College of Cardiology suggests that baseline cardiovascular assessment is recommended before initiating propranolol, and initial dosing typically ranges from 30-60 mg daily in divided doses or as a single dose with long-acting formulations 1
• Propranolol may mask symptoms of hypoglycemia in susceptible patients, according to Circulation 2
• The American College of Cardiology advises that abrupt discontinuation of propranolol should be avoided to prevent rebound hypertension or tachycardia 1

Monitoring and Dosing

• The American College of Cardiology recommends monitoring for potential adverse effects of propranolol, including hypotension, bradycardia, bronchospasm, and worsening heart failure 1
• The maximum maintenance dose of propranolol is typically 40-160 mg daily in divided doses or as a single dose with long-acting formulations, according to the American College of Cardiology 1

Propranolol Dosing and Monitoring for Anxiety Treatment

Patient Monitoring and Contraindications

• The American Heart Association recommends monitoring for hypotension and bradycardia, especially at higher doses, in patients taking propranolol for anxiety treatment 3
• Propranolol is contraindicated in patients with asthma or obstructive airway disease, decompensated heart failure, second or third-degree heart block, and history of hypoglycemic episodes, as recommended by the American College of Cardiology 3
• Baseline assessment of heart rate and blood pressure is recommended for patients taking propranolol, with no routine monitoring required for most patients, according to the American Heart Association 3

Propranolol Administration Guidelines

Dosing and Administration

• Administer propranolol with food to reduce the risk of hypoglycemia in patients, and hold doses during times of diminished oral intake or vomiting, as recommended by the American Academy of Pediatrics 4
• Lower doses may be required for patients with comorbidities or those experiencing adverse effects, according to the American Academy of Pediatrics 4

Special Patient Considerations

• The American Academy of Pediatrics suggests that propranolol doses should be adjusted in patients with certain conditions, such as those requiring lower doses 4

Propranolol Dosing for Physical Symptoms of Anxiety in Adults

Patient Selection and Contraindications

• The American Heart Association recommends excluding patients with second or third-degree heart block, decompensated heart failure, significant left ventricular dysfunction, asthma or reactive airway disease, hypotension, cardiogenic shock, recent or ongoing hypoglycemic episodes, and sinus node dysfunction without a pacemaker from propranolol treatment 5, 6
• Patients with physical symptoms of anxiety, such as tremor, palpitations, tachycardia, sweating, and other autonomic symptoms, are most likely to benefit from propranolol treatment, according to the American College of Cardiology 5

Mandatory Pre-Treatment Assessment and Monitoring

• The American Heart Association suggests performing a baseline assessment including heart rate and blood pressure measurement, cardiovascular examination with auscultation, and screening for history of bronchospasm, diabetes, and concurrent medications that affect cardiac conduction before initiating propranolol treatment 5, 6
• Monitoring for hypotension and bradycardia is recommended, especially during dose escalation, as stated by the American College of Cardiology 5, 6

Critical Safety Considerations

• The American Heart Association advises against abruptly discontinuing propranolol after chronic use, as this can precipitate rebound hypertension, tachycardia, or angina, and recommends tapering gradually when discontinuing 5, 6
• Common adverse effects of propranolol include fatigue, bradycardia, hypotension, dizziness, cold extremities, and potential worsening of heart failure, as reported by the American College of Cardiology 5, 6

Propranolol Dosing and Administration

Introduction to Propranolol

• The American College of Cardiology recommends starting propranolol immediate-release 80-160 mg daily in 2 divided doses, or propranolol long-acting 80 mg once daily, titrating up to 120-160 mg daily for maintenance, with a maximum of 640 mg daily if needed 7

Dosing Considerations

• For hypertension, the American College of Cardiology suggests an immediate-release formulation of 80-160 mg daily divided into 2 doses 7
• In hypertensive emergencies, the American College of Cardiology prefers labetalol (combined alpha/beta blocker) with a dose of 0.3-1.0 mg/kg slow IV injection (maximum 20 mg) every 10 minutes, or 0.4-1.0 mg/kg/h IV infusion up to 3 mg/kg/h, contraindicated in reactive airways disease, heart block, or bradycardia 8

Pre-Treatment Assessment and Monitoring

• The British Journal of Dermatology guidelines state that routine blood work (CBC, renal, liver, thyroid function) is not required before starting propranolol in otherwise healthy adults, and ECG and echocardiogram are only needed in selected cases with cardiac concerns 9
• The American College of Cardiology recommends no routine vital sign monitoring required between appointments if the patient is stable and asymptomatic 9
• Elderly patients may require lower doses due to altered pharmacokinetics, as suggested by the American College of Cardiology 8

Safety Warnings

• The American College of Cardiology advises to never abruptly discontinue propranolol, especially after chronic use, and to taper gradually over several weeks when discontinuing 7
• Absolute contraindications include second or third-degree heart block, decompensated heart failure, asthma or obstructive airway disease, as recommended by the American College of Cardiology 7, 8
• The American College of Cardiology warns to avoid routine combination with nondihydropyridine calcium channel blockers (diltiazem, verapamil) due to increased risk of bradycardia and heart block 7

Propranolol Titration and Monitoring

Pre-Treatment Assessment

• The American Heart Association recommends screening for absolute contraindications, including second or third-degree heart block, decompensated heart failure, asthma/obstructive airway disease, cardiogenic shock, and sinus node dysfunction without pacemaker, before initiating propranolol 10
• The British Journal of Dermatology suggests performing an ECG and echocardiogram in patients with suspected cardiac abnormalities or segmental head/neck conditions before starting propranolol 11
• Assess for relative contraindications, such as history of bronchospasm, diabetes, hypotension, and concurrent medications affecting cardiac conduction, as recommended by the American Heart Association 10

Critical Safety Considerations

• The American Heart Association warns of serious adverse effects, including worsening heart failure, bronchospasm, and severe bradycardia, which can occur during propranolol treatment 10
• Monitor for metabolic effects, such as masking of hypoglycemia symptoms in diabetic patients, as recommended by the American Heart Association 10
• Temporarily discontinue propranolol if the patient has wheezing requiring treatment or significantly reduced oral intake or vomiting, as suggested by the British Journal of Dermatology 11

Drug Interactions

• Avoid routine combination of propranolol with non-dihydropyridine calcium channel blockers, such as diltiazem and verapamil, due to increased risk of bradycardia and heart block, as recommended by the American Heart Association 10

Propranolol for Situational Anxiety

Introduction to Propranolol Use

• The Japanese Society of Anxiety and Related Disorders deprecates propranolol based on negative evidence for generalized social anxiety disorder, but it is effective for performance anxiety and specific situational triggers with prominent somatic symptoms 12

Dosing and Administration

• The Japanese Society of Anxiety and Related Disorders suggests that propranolol is not suitable for chronic anxiety treatment, but rather for situational use, with a maximum single dose of 40 mg 12

Patient Selection and Contraindications

• Propranolol is most effective for patients with physical/somatic symptoms of autonomic hyperactivity, such as tremor, palpitations, and sweating, rather than those with predominantly psychological symptoms 12

Propranolol for Situational Anxiety

Patient Selection and Dosing

• The American Heart Association recommends propranolol for patients with situational anxiety and prominent somatic symptoms, such as tremor, palpitations, and sweating, with a starting dose of 10-20 mg taken 30-60 minutes before the anxiety-provoking event 13

Critical Safety Warnings

• The American Diabetes Association warns that propranolol masks symptoms of hypoglycemia in diabetic patients, and should be used with extreme caution in patients with diabetes or history of hypoglycemic episodes 13

Precautions Before Taking Propranolol

Mandatory Pre-Treatment Assessment

• The American Academy of Pediatrics recommends obtaining electrocardiography, particularly in younger infants, those with low heart rate, or those with abnormal cardiac examination findings 14
• The American Academy of Pediatrics suggests considering cardiology consultation if there is family history of congenital heart disease, though pretreatment cardiac screening appears of limited value in patients with unremarkable cardiac history and examination 14
• The American Academy of Pediatrics recommends auscultating lungs for wheezing or evidence of obstructive airway disease 14

Special Population Considerations

• The American Academy of Pediatrics recommends considering inpatient hospitalization for initiation in infants 8 weeks or younger, preterm infants less than 48 weeks postconceptional age, those with poor social support, or those with cardiac/pulmonary risk factors 14
• The American Academy of Pediatrics suggests reducing hypoglycemia risk by administering propranolol and feeding at intervals not exceeding 8 hours (or 6 hours in younger infants) 14
• The American Academy of Pediatrics recommends closely monitoring or temporarily reducing dosing in children with any acute illness, especially those interfering with normal oral intake or associated with vomiting or diarrhea 14

Critical Safety Warnings

• The American Academy of Pediatrics recommends planning for gradual taper over 1-3 weeks when discontinuation of propranolol is necessary 14

Propranolol Dosing Guidelines

Introduction to Propranolol Formulations

• The American College of Cardiology recommends propranolol immediate-release formulation to be dosed 2-4 times daily, while the long-acting formulation is dosed once daily 15, 16

Pharmacokinetics and Dosing

• The oral immediate-release half-life of propranolol is 3-6 hours, requiring multiple daily doses 15
• Typical dosing frequency for immediate-release propranolol is 3-4 times daily for most indications 15
• Alternative dosing of twice daily is acceptable for certain indications like hypertension, as recommended by the American College of Cardiology 16
• The extended-release half-life of propranolol is 8-20 hours, allowing for once daily dosing 15

Indication-Specific Dosing

• For atrial fibrillation rate control, the American College of Cardiology recommends 10-40 mg of immediate-release propranolol, 3-4 times daily 15
• For hypertension, the American College of Cardiology recommends 80-160 mg daily divided into 2 doses (twice daily) of immediate-release propranolol 16

Critical Dosing Considerations

• For acute settings requiring rapid effect, the American College of Cardiology recommends an IV dose of 1 mg over 1 minute, which may be repeated every 2 minutes as needed, up to 3 doses 15
• The IV half-life of propranolol is 2.4 hours 15

Propranolol Dosing for Anxiety in Adults

Dosing Regimens

• The American College of Cardiology recommends an initial dose of 40 mg twice daily (80 mg total daily) of immediate-release propranolol for ongoing anxiety, with a typical effective range of 80-160 mg daily in 2 divided doses 17
• The American College of Cardiology suggests that propranolol LA (long-acting) can be used at a dose of 80 mg once daily, titrated to 120-160 mg once daily 17
• The American College of Cardiology advises that propranolol must be tapered gradually over several weeks when discontinuing to prevent rebound hypertension, tachycardia, or angina 17

Safety Considerations for Propranolol Use After Stimulants

Absolute Contraindications

• Cardiogenic shock is an absolute contraindication to initiating propranolol; patients should be screened for this condition before any dose is given. 18

Administration Recommendations to Reduce Metabolic Risk

• Propranolol should be taken with food to lessen the likelihood of hypoglycemia, particularly when the patient has not eaten recently. 18

Monitoring for Excessive Beta‑Blockade

• Clinicians should observe patients for signs of excessive beta‑blockade after propranolol administration, including dizziness or light‑headedness, marked fatigue, heart rate falling below 50 beats/min, systolic blood pressure dropping below 90 mm Hg, and new or worsening shortness of breath/wheezing. 19

Impact on Hypoglycemia Detection

• Propranolol can mask the typical adrenergic warning signs of low blood glucose (e.g., tremor, rapid heartbeat, sweating); therefore, patients—especially those with diabetes or a history of hypoglycemia—should monitor blood glucose more frequently and rely on non‑adrenergic cues such as hunger, confusion, or sweating to detect hypoglycemia. 19

Contraindications and Safety Monitoring for Propranolol in Performance‑Related Anxiety

Absolute Contraindications

• Asthma, chronic obstructive pulmonary disease, or any obstructive airway disease constitute an absolute contraindication to propranolol because non‑selective β‑blockade can precipitate bronchospasm. 20
• Sinus bradycardia or sinus node dysfunction in the absence of a pacemaker is an absolute contraindication to propranolol, given the risk of profound heart‑rate slowing. 20

Signs of Excessive Beta‑Blockade

• Clinicians should watch for patient‑reported dizziness, marked fatigue, or light‑headedness as potential indicators of excessive β‑blockade when propranolol is used for situational anxiety. 20

Contraindications and Safety Considerations for Propranolol in Performance‑Related Anxiety

Absolute Contraindications

Mandatory Pre‑Treatment Assessment

Discontinuation Guidance

Drug Interaction Warning

Propranolol Clinical Guidance: Indications, Contraindications, Interactions, and Alternatives

Supraventricular Tachycardia – Oral Therapy

• The American College of Cardiology recommends initiating oral propranolol for ongoing management of supraventricular tachycardia at a dose of 30–60 mg per day, divided into two doses or given as a single dose of a long‑acting formulation; the maintenance dose may be increased to 40–160 mg per day as needed. 22

Absolute Contraindications

• According to the American College of Cardiology, propranolol should not be used in patients with any of the following absolute contraindications:

Major Drug Interactions

• The American College of Cardiology advises avoiding routine co‑administration of propranolol with non‑dihydropyridine calcium‑channel blockers (e.g., diltiazem, verapamil) because of a markedly increased risk of bradycardia and heart block. 22
• Propranolol is contraindicated when used together with the anti‑arrhythmic agent dofetilide. 22
• Because propranolol is metabolized by CYP2D6, CYP1A2, and CYP2C19, concomitant use of CYP3A4 inhibitors such as diltiazem or verapamil can further elevate propranolol concentrations and exacerbate the interaction risk. 22

Alternative Beta‑Blockers When Propranolol Is Unsuitable

• The American College of Cardiology notes that these alternatives do not require renal dose adjustment (metoprolol) or have well‑characterized dosing limits for patients with renal impairment (atenolol, nadolol). 22

Considerations for Patients with Reactive Airway Disease

• For individuals with a history of bronchospasm, the American College of Cardiology suggests using cardioselective β‑blockers (e.g., metoprolol, atenolol) with extreme caution, recognizing that all β‑blockers retain some risk of bronchospasm. Non‑dihydropyridine calcium‑channel blockers (diltiazem, verapamil) may be considered for rate control but are not effective for tremor or anxiety indications. 22

Propranolol as Dual Therapy for Hypertension and Situational (Performance‑Type) Anxiety

Mechanism and Indicated Comorbidities

Guideline‑Directed Blood‑Pressure Management

Dosing Strategies for Combined Indication

Chronic Daily Dosing (Preferred for Frequent Anxiety Episodes)

Hybrid Dosing (For Infrequent Performance Situations)

Safety Considerations

Drug‑Interaction Alerts

Comparative Pharmacology

Evidence Summary

First‑line Antihypertensive Therapy Recommendations

Hypertension Pharmacologic Choices

Propranolol Dosing and Monitoring in Hyperthyroidism

Dosing Intervals

• Oral propranolol doses should be spaced no more than 8 hours apart to maintain adequate beta‑blockade and minimize symptom recurrence. 28

Post‑Initiation Monitoring

• After the first dose and after any dose increase of ≥0.5 mg/kg, clinicians should reassess resting heart rate and systolic blood pressure within 1–2 hours to confirm therapeutic effect and detect excessive beta‑blockade. 28

Acute Illness Management

• If the patient experiences gastrointestinal upset (e.g., vomiting or diarrhea) that compromises oral intake, or any acute illness that reduces food consumption, the propranolol dose should be temporarily reduced or held until oral intake normalizes; dosing can then be resumed at a lower level and titrated upward as needed. 28

Intravenous Administration for Emergency Surgical Preparation

• A single intravenous dose of propranolol 0.15 mg/kg can achieve rapid beta‑blockade (within <1 hour), providing prompt control of tachycardia when urgent surgical preparation is required. 29

Blood Pressure Reduction Targets with Propranolol

Therapeutic Goals

• In patients with hypertension (including those who also have headache), propranolol therapy should aim to lower systolic/diastolic pressure by at least 20/10 mm Hg, with an ideal target of < 140/90 mm Hg. 30

Contraindications to Propranolol for Situational Anxiety

Absolute Contraindications

• Patients with obstructive airway disease (e.g., asthma or chronic obstructive pulmonary disease) should not receive propranolol because non‑selective β‑blockade can precipitate life‑threatening bronchospasm. 31
• Individuals with second‑ or third‑degree atrioventricular (AV) block who do not have a pacemaker are contraindicated due to the risk of progressing to complete heart block. 31
• Patients with decompensated heart failure or cardiogenic shock should avoid propranolol because it can further reduce cardiac output. 31
• Persons with a resting systolic blood pressure below 90 mm Hg are contraindicated, as propranolol may cause additional hypotension. 31

Propranolol for Situational and Performance Anxiety – Guideline Summary

Indications and Endorsements

• The Japanese Society of Anxiety and Related Disorders advises against using propranolol for generalized social anxiety disorder, but endorses its use for performance‑related anxiety when somatic symptoms (e.g., tremor, tachycardia, sweating) are prominent. 32

Patient Selection

• Best candidates are adults who face infrequent, predictable anxiety‑provoking situations and whose main manifestations are physical autonomic hyperactivity (tremor, rapid heartbeat, sweating).
• Poor candidates are individuals with chronic daily anxiety, primarily psychological symptoms (worry, rumination), or a need for continuous treatment; these patients should be managed with SSRIs/SNRIs or cognitive‑behavioral therapy instead of propranolol. 32

Evidence Strength and Consensus

• The recommendation to use propranolol for situational anxiety is supported by strong guideline consensus from the American College of Cardiology, the American Heart Association, and the Japanese Society of Anxiety and Related Disorders. 32

Alternative First‑Line Pharmacotherapy for Chronic Anxiety

• For chronic anxiety disorders, SSRIs (e.g., escitalopram, sertraline) or SNRIs (e.g., venlafaxine) are considered first‑line treatments; beta‑blockers such as propranolol are not recommended. 32

Contraindicated Uses

• International guidelines explicitly deprecate prescribing propranolol for chronic daily anxiety, emphasizing that SSRIs/SNRIs provide superior efficacy for this indication. 32

Non‑Selective Beta‑Blockade: Risks and Cardioselective Alternatives

Respiratory Risks

• Propranolol blocks both β1 and β2 receptors; β2 antagonism in bronchial smooth muscle produces bronchoconstriction, making the drug absolutely contraindicated in patients with asthma or obstructive airway disease. The American College of Cardiology/American Heart Association (ACC/AHA) highlights this contraindication. 33
• Even mild wheezing or chronic obstructive pulmonary disease warrants the use of a cardioselective β1‑blocker (e.g., metoprolol or esmolol) at reduced doses instead of propranolol. 33

Vascular Effects

• β2‑receptor blockade in vascular smooth muscle leads to vasoconstriction, which can cause cold extremities and may exacerbate peripheral vascular disease. 33

Guideline Recommendations for Cardioselective Substitution

• The ACC/AHA guidelines advise switching from non‑selective agents to cardioselective β1‑specific drugs when the risks of non‑selectivity are present. 33
• Metoprolol (tartrate or extended‑release) and atenolol are identified as relatively selective β1‑blockers, whereas propranolol lacks this selectivity. 33
• In patients with borderline pulmonary function or mild reactive airway disease, the guidelines recommend initiating therapy with a short‑acting cardioselective β1‑blocker (e.g., low‑dose metoprolol) rather than propranolol. 33
• Although cardioselective agents reduce pulmonary risk, they still carry a dose‑related risk of bronchospasm, so extreme caution is required in any history of reactive airway disease. 33

Clinical Application in Anxiety Management

• For situational anxiety in adults without cardiac or respiratory contraindications, propranolol’s non‑selective blockade can be advantageous because β2 antagonism attenuates peripheral anxiety manifestations such as tremor, sweating, and palpitations. However, the same non‑selectivity makes propranolol unsuitable for any patient with even mild asthma or COPD, where a cardioselective agent would be mandatory if beta‑blockade is needed. 33

Propranolol Dosing, Contraindications, and Evidence for Situational Anxiety

Dosing Recommendations (American College of Cardiology / American Heart Association)

• The ACC/AHA guidelines recommend an initial daily propranolol dose of 30–60 mg (either divided or as a single dose of a long‑acting formulation) and a maintenance range of 40–160 mg per day for cardiovascular indications, which is extrapolated to off‑label use in situational anxiety. [34] [35] 36

Cardiac Contraindications (American College of Cardiology)

• Propranolol should not be prescribed to individuals with second‑ or third‑degree atrioventricular block or sinus node dysfunction unless a pacemaker is in place. [34] [35] 36
• Patients with decompensated heart failure or severe left‑ventricular systolic dysfunction are absolute contraindicated for propranolol therapy. [34] [35] 36

Respiratory Contraindications (American College of Cardiology)

• Active asthma, chronic obstructive pulmonary disease with bronchospasm, or any obstructive airway disease constitute absolute contraindications because non‑selective β‑blockade can precipitate life‑threatening bronchospasm. [34] [35] 36

Drug Interaction Precautions (American College of Cardiology)

• Concomitant use of propranolol with non‑dihydropyridine calcium‑channel blockers (e.g., diltiazem, verapamil) is discouraged due to a markedly increased risk of severe bradycardia and heart block. [34] [35] 36
• Caution is advised when propranolol is combined with other agents that depress cardiac conduction such as digoxin, amiodarone, or ivabradine, because of additive bradycardic effects. [34] [35] 36

Alternative Beta‑Blockers (American College of Cardiology)

• Both metoprolol and atenolol are cited as possible alternatives when propranolol is unsuitable, though evidence for anxiety efficacy is weaker. [34] [36]

Evidence Strength and Guideline Consensus (American College of Cardiology / American Heart Association / Japanese Society of Anxiety and Related Disorders)

• The recommendation to use propranolol for performance‑type situational anxiety is supported by strong guideline consensus from the ACC, AHA, and the Japanese Society of Anxiety and Related Disorders, reflecting Class I evidence for the dosing ranges in cardiovascular contexts that inform its off‑label anxiety use. [34] [35] 36

Follow‑Up Monitoring Recommendations for Propranolol in Anxiety

Routine Follow‑Up Visits

• In stable adults receiving a consistent low‑dose propranolol regimen for anxiety, routine follow‑up visits are not required when the patient remains asymptomatic and well‑controlled. 37
• Scheduled office visits are unnecessary if heart rate and blood pressure remain stable, as these parameters do not need periodic monitoring between appointments in this population. 37
• Follow‑up evaluation should be initiated only if the patient develops symptoms suggestive of excessive beta‑blockade or other adverse effects. 37

Temporary Holding of Propranolol During Acute Illness

Guidance for Short‑Term Interruption

• In patients who develop markedly reduced oral intake, vomiting, or wheezing that necessitates treatment, propranolol may be held temporarily without a taper; this approach is endorsed by the British Journal of Dermatology (2018) 38.
• Once oral intake returns to normal, the medication should be re‑started at a lower dose and then up‑titrated to the previous therapeutic level, as recommended in the same guideline 38.

Distinction from Permanent Discontinuation

• A permanent discontinuation of propranolol for cardiovascular indications always requires a gradual taper over several weeks, contrasting with the temporary hold strategy described above 38.

Propranolol Guidelines for Infantile Hemangioma (Pediatric Use)

Dosing Regimens

• Initiate therapy at 1 mg/kg/day divided into 2–3 doses with food; increase after 24 h to a maintenance dose of 2 mg/kg/day for uncomplicated hemangiomas, with a maximum of 3 mg/kg/day for inadequate response. [39][40]
• In special populations (e.g., suspected PHACES syndrome, pre‑term infants <48 weeks post‑conception, infants <8 weeks old, low‑birth‑weight or faltering‑growth infants, those with hyperinsulinism or prior hypoglycemia, and infants with poor feeding or metabolic/neurologic disorders), start at a lower dose of 0.5 mg/kg/day. [39][40]

Administration Considerations

• Give propranolol with or after feeding to lower the risk of hypoglycemia. 40
• Hold doses during periods of reduced oral intake, vomiting, or acute illness. [39][40]
• Maintain dosing intervals ≤8 hours (≤6 hours in younger infants) to ensure steady plasma levels. 40
• Use a 5 mg/5 mL oral suspension to minimize dosing errors. 40

Duration of Therapy & Discontinuation

• Most patients do not require treatment beyond 17 months of age. 39
• It is safe to stop propranolol abruptly without taper when treating infantile hemangiomas. 39

Pre‑Treatment Assessment

• Perform a cardiovascular examination with auscultation in all patients before starting therapy. 39
• Electrocardiogram (ECG) is indicated only if any of the following are present: abnormal heart rate for age, strong family history of sudden cardiac death or arrhythmia, episodes of loss of consciousness, maternal connective‑tissue disease, or suspected cardiac abnormality. 39
• Echocardiogram is required when segmental head/neck hemangiomas (suspected PHACES), abnormal cardiac examination, or known cardiac disease are identified. [39][40]
• Obtain a baseline glucose measurement in patients at risk for hypoglycemia (pre‑term, low‑weight, faltering growth, neonates, or prior hypoglycemia). [39][40]
• Routine laboratory work (CBC, renal, liver, thyroid panels) is not required in otherwise healthy children. 39

PHACES‑Syndrome Specific Assessment

• Perform a brain MRI/MRA before initiating full‑dose propranolol. [39][40]
• Ensure ECG and echocardiogram are interpreted by a pediatric cardiologist. [39][40]
• Discuss any identified arterial stenosis or agenesis with a pediatric neurologist. 39

Post‑Initiation Monitoring

• For high‑risk pediatric patients (age < 4 weeks, pre‑term, faltering growth, feeding difficulties, or significant comorbidities), measure heart rate and blood pressure immediately before the first dose and monitor every 30 minutes for 2–4 hours after the dose. [40][39]40
• Stable patients on maintenance therapy should have follow‑up visits every 2–3 months; dose adjustments may be made based on weight by the clinic, primary‑care physician, or parents using written instructions. 39
• In low‑risk patients who remain asymptomatic, routine heart rate and blood pressure checks between appointments are not required. 39

Absolute Contraindications

• Second‑ or third‑degree atrioventricular block (without a pacemaker). 39
• Decompensated heart failure or severe left‑ventricular dysfunction. 39
• Asthma or obstructive airway disease (risk of life‑threatening bronchospasm). 39
• Cardiogenic shock. 39
• Sinus node dysfunction or sinus bradycardia (without a pacemaker). 39
• Severe hypotension (systolic BP < 90 mm Hg). 39
• Recent or ongoing hypoglycemic episodes. 39
• Known hypersensitivity to propranolol. 39

Propranolol Dose Equivalence for Atenolol 75 mg

Dose Conversion Recommendations

• For a patient receiving atenolol 75 mg once daily, replace it with propranolol 120–160 mg per day—either as immediate‑release 60–80 mg twice daily or as a long‑acting 120–160 mg once‑daily dose. (AHA/ACC/HRS guideline) 41

Guideline‑Based Maintenance Dosing

• The 2014 AHA/ACC/HRS atrial‑fibrillation guideline lists standard maintenance doses as atenolol 25–100 mg once daily and propranolol 10–40 mg three to four times daily (total 30–160 mg/day). (AHA/ACC/HRS guideline) 41
• Because atenolol 75 mg lies in the mid‑to‑upper therapeutic range, an equivalent propranolol dose of 120–160 mg daily is appropriate. (AHA/ACC/HRS guideline) 41

Mandatory Pre‑Conversion Assessment (Contraindications)

• Before switching, screen for absolute contraindications to propranolol:

Drug‑Interaction Alert

• Avoid co‑administration of propranolol with non‑dihydropyridine calcium‑channel blockers (e.g., diltiazem, verapamil) because the combination markedly increases the risk of severe bradycardia and heart block; this risk is lower with atenolol. (AHA/ACC/HRS guideline) 41

Common Conversion Pitfall

• A 1 : 1 milligram conversion is incorrect; propranolol 75 mg daily provides substantially less beta‑blockade than atenolol 75 mg. The recommended propranolol range of 120–160 mg daily is necessary to achieve equivalent cardiovascular effects. (AHA/ACC/HRS guideline) 41